Fig. 2.
Fig. 2. BSAP/Pax5A-expressing EML cells successfully acquire the myeloid lineage commitment marker CD11b. (A) B220+/CD11b− EML cells were placed in culture at 3 × 105 cells/mL and then induced to differentiate into B220hi/CD11b+ and B220lo/CD11b+ cells with 10% WEHI-3B conditioned supernatant (contains murine IL-3) and 10 μmol/L ATRA. Flow cytometry was performed on days 0 and 3. Control EML clones EML/Hyg-1 and EML/Hyg-3 and Pax5A/BSAP-expressing EML clones EML/Pax5A-3 and EML/Pax5A-5 were induced to differentiate as described in (A). On days 1, 2, and 3 of differentiation, a small sample of cells was removed from the culture, and differentiation to B220hi/CD11b+ (B) and B220lo/CD11b+ (C) cells was determined by flow cytometry.

BSAP/Pax5A-expressing EML cells successfully acquire the myeloid lineage commitment marker CD11b. (A) B220+/CD11b EML cells were placed in culture at 3 × 105 cells/mL and then induced to differentiate into B220hi/CD11b+ and B220lo/CD11b+ cells with 10% WEHI-3B conditioned supernatant (contains murine IL-3) and 10 μmol/L ATRA. Flow cytometry was performed on days 0 and 3. Control EML clones EML/Hyg-1 and EML/Hyg-3 and Pax5A/BSAP-expressing EML clones EML/Pax5A-3 and EML/Pax5A-5 were induced to differentiate as described in (A). On days 1, 2, and 3 of differentiation, a small sample of cells was removed from the culture, and differentiation to B220hi/CD11b+ (B) and B220lo/CD11b+ (C) cells was determined by flow cytometry.

Close Modal

or Create an Account

Close Modal
Close Modal